-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We adjust our target price to USD50 from USD47, implying 15.1x our 2026 EPADS, below its historical forward P/E average of 24x-28x, to reflect concerns over its long-term competitive edge. We adjust our EPADS forecasts to DKK21.05 from DKK20.60 for 2026 and to DKK21.70 from DKK22.30 for 2027, to account for the updated guidance while also considering the continued pricing pressure. Novo Nordisk raised its 2026 outlook, with adjusted sales and operating profit now expected to decline 4%-12% CER (vs. prior -5% to -13%), reflecting stronger GLP-1 expectations, particularly for the Wegovy pill. In Q1 2026, adjusted sales (excluding the rebate provisions reversal) fell 10% (-4% CER) on lower realized prices, particularly in the U.S., partially offset by volume growth. The Wegovy pill's strong launch trajectory is encouraging, with international rollout expected in 2H 2026. However, persistent U.S. pricing pressure, mixed clinical data (CagriSema setbacks), and intensifying competition warrant close monitoring.